F2RL1 and asthma: Our results indicated the potential of this molecule for fast track studies from translational to clinical settings, even more that PAR-2 antagonist FSLLRY-NH2 can be developed as a nebulizer or aerosolized formulation and used as an adjuvant therapy for treatment and managing of asthma.